Objective To describe the case histories of two patients who developed acquired haemophilia A following treatment with alemtuzumab for multiple sclerosis. Results Two patients, a 48-year-old woman and a 31-year-old woman, developed acquired haemophilia A 21 months after their second doses of alemtuzumab. Both presented with spontaneous bruising, and the second case reported menorrhagia. One patient required treatment to control bleeding. Both patients responded to treatment with prednisolone and cyclophosphamide to eliminate the inhibitor. Conclusions Acquired haemophilia A is a rare complication following treatment with alemtuzumab. Activated partial thromboplastin time and prothrombin time should be performed in cases of abnormal bleeding in which the platelet count is normal, to facilitate timely diagnosis and prevention of major bleeding complications.

中文翻译：

---

阿仑单抗治疗多发性硬化症合并获得性A型血友病2例报告

目的 描述 2 例多发性硬化症阿仑单抗治疗后发展为获得性血友病 A 的患者的病史。结果 两名患者，一名 48 岁女性和一名 31 岁女性，在第​​二剂阿仑单抗治疗 21 个月后发展为获得性血友病 A。两人都出现自发性瘀伤，第二例报告月经过多。一名患者需要治疗以控制出血。两名患者都对泼尼松龙和环磷酰胺治疗以消除抑制剂有反应。结论 获得性血友病 A 是阿仑单抗治疗后的罕见并发症。在血小板计数正常的异常出血的情况下，应进行活化部分凝血活酶时间和凝血酶原时间，